Clinical Policy: Glycerol Phenylbutyrate (Ravicti)
Customize your policy alerts
Sign up for all Health Net policy alerts
Know when Health Net releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs medical necessity criteria, prior authorization, and continuation requirements for glycerol phenylbutyrate (Ravicti) for treatment of urea cycle disorders across Health Net lines of business (Commercial, HIM, Medicaid). It specifies diagnostic confirmation, prescriber experience, stepwise redirection to alternatives, dosing limits, and approval durations.
Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.
Added stepwise redirection requiring use of generic sodium phenylbutyrate first, then Pheburane if intolerance or contraindication, for continuation of therapy and requests.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.